Journal
BLOOD
Volume 116, Issue 22, Pages 4639-4645Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-04-281717
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL096497, HL096497] Funding Source: Medline
Ask authors/readers for more resources
Immune thrombocytopenia (ITP) is an autoantibody-mediated bleeding disorder with both accelerated platelet destruction and impaired platelet production. We and others have described impaired regulatory CD4(+)CD25(hi) T cells (Treg) numbers and/or suppressive function in ITP patients. Clinical trials using thrombopoietic agents to stimulate platelet production have shown favorable outcomes in ITP patients, but information on the immunologic responses of treated patients are lacking.We studied the immunologic profile of chronic ITP patients before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9). Treg activity, as measured by suppression of proliferation of autologous CD4(+) CD25(-) cells, was improved in patients on treatment (P <.05), and the improvement correlated with reduction in interleukin-2-producing CD+ cells, consistent with dampening of immune responses. There was a concomitant increase in total circulating transforming growth factor-beta 1 (TGF-beta 1) levels (P = .002) in patients on treatment, and the levels of TGF-beta 1 correlated with the degree of improvement in platelet counts (r = .8, P = .0002). This suggests that platelets in patients on TPO-R treatment may play a role in improving Treg function, either directly or indirectly by enhanced release of TGF-beta 1 as a result of greater platelet turnover. In conclusion, our findings suggest that thrombopoietic agents in patients with ITP have profound effects to restore immune tolerance. (Blood. 2010;116(22): 4639-4645).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available